CtDNA comprises genetic material released into the bloodstream because of tumor cell necrosis, while cell-free DNA originates from non-cancerous cells and lacks pathological molecular alterations.12 Examination of KRAS mutations within ctDNA is an invaluable strategy for cancer detection and surveillance, providing essential insights into tumor genetics and treatment efficacy. This evidence concerns the gene KRAS and cancer.